MULTIPLE SCLEROSIS

Rivista

Codice:

E113973

ISSN:

1352-4585

Dati Generali

Pubblicazioni (65)

A Meta-Analysis Of Methylprednisolone In Recovery From Multiple Sclerosis Exacerbations

Articolo

A real-world study of Alemtuzumab in a cohort of Italian patients

Abstract

Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab

Articolo

Acute and chronic synaptic pathology in multiple sclerosis gray matter

Articolo

Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation

Abstract

Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials

Contributo in Atti di convegno

Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study

Abstract

An MMP sensitive contrast agent: an approach for MRI detection of CNS pathological events in multiple sclerosis

Articolo

Association of MRI leptomeningeal enhancement with disability worsening in progressive multiple sclerosis: A clinical and post-mortem study

Articolo

Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies

Articolo

Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies

Articolo

Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-γ and interleukin-4 response

Articolo

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.

Articolo

Comparative effectiveness of Cladribine tablets vs other drugs in relapsing-remitting multiple sclerosis: an approach merging randomized controlled trial with real life data

Abstract

Comparative effectiveness of dimethyl fumarate, teriflunomide, interferon-beta and glatiramer acetate on newly diagnosed patients: a propensity score-matched analysis from a multicenter Italian group

Abstract

Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis – Yes

Articolo

Corticla pathology in multiple sclerosis: expression of glutamate transporter EAAT2

Contributo in Atti di convegno

Cytomegalovirus reactivation during alemtuzumab treatment in a patient with multiple sclerosis

Contributo in Atti di convegno

Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study

Articolo

Differential degree of blood-brain barrier permeability during experimental autoimmune encephalomyelitis measured by gadolinium-enhancement magnetic resonance imaging

Articolo

Disability assessment in the Google Maps era: a pilot study

Abstract

EFFECTS OF IMMUNOMODULATORY TREATMENT WITH SUBCUTANEOUS INTERFERON BETA-1A ON COGNITIVE DECLINE IN MILDLY DISABLED PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS

Articolo

Effectiveness of Natalizumab on Multiple Sclerosis patients: the Italian registry experience

Abstract

Epigenetic mechanisms regulate T helper 17 and T regulatory cells during pregnancy in multiple sclerosis.

Abstract

Estrogen receptor-alpha regulates epigenetic changes on genomic regulatory regions: potential biomarkers in multiple sclerosis outcomes

Abstract

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab

Articolo

Extended interval dosing of natalizumab: is efficacy preserved?

Abstract

Functional connectivity changes within specific networks parallel the clinical evolution of multiple sclerosis

Articolo

Gut microbiota alteration in Clinically Isolated Syndrome: a pilot study

Abstract

High-dose interferon-beta-1b (500 mcg every-other-day, subcutaneously) treatment in MS patients. Long-term evaluation and longitudinal comparison with preceding treatment with lower IFN beta dose

Contributo in Atti di convegno

How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study

Abstract

How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study

Abstract

Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning.

Articolo

Interferon-beta-1b in multiple sclerosis: comparing two different doses (the OPTIMS Study)

Contributo in Atti di convegno

Involvement of the choroid plexus in multiple sclerosis autoimmune inflammation

Contributo in Atti di convegno

Long-term predictivity analysis trial of a treatment response marker to immunomodulatory drug in MS and evaluation of high-dose interferon beta treatment

Contributo in Atti di convegno

Longitudinal alteration of gut microbiome composition in subjects with Multiple Sclerosis during Dimethyl Fumarate therapy: a one-year follow-up study

Abstract

MS Italian patients manifesting natalizumab-related PML between 2009 and 2014. Report of the Italian group for MS-PML study

Abstract

Management of multiple sclerosis patients after the 24th Natalizumab course: the Ty-STOP study

Contributo in Atti di convegno

Mitoxantrone-related acute myeloid leukaemia, induced one year after the discontinuation of mitoxantrone therapy

Abstract

Multiparametric MR investigation of the motor pyramidal system in patients with 'truly benign' multiple sclerosis

Articolo

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS

Articolo

Neuronal and synaptic pathology in grey matter demyelinating lesions in multiple sclerosis

Contributo in Atti di convegno

Occurrence of ecchymotic angioedema-like cutaneous lesions as a possible side effect of fingolimod.

Articolo

Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis.

Articolo

Progranulin expression in brain tissue and cerebrospinal fluidlevels in multiple sclerosis

Articolo

Qualitative and quantitative analysis of antibody response against IFNβ in patients with multiple sclerosis

Articolo

Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.

Articolo

Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis

Articolo

Ready for a new saga? Th17 and not Th1 are selectivly increate in active multiple sclerosis and undergo apoptosis with interferon beta

Contributo in Atti di convegno

Reliability and acceptability of the Multiple Sclerosis Quality of Life-29 questionnaire in an English-speaking cohort

Articolo

Role of Th22 expansion in multiple sclerosis disease activity

Contributo in Atti di convegno

SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

Articolo

Sars-CoV2 infection in pregnant women with multiple sclerosis

Articolo

Shift from fingolimod to alemtuzumab: what happens next?

Abstract

Six year prospective immunological study of alemtuzumab treated patients: identification of markers of the clinical response

Abstract

Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience

Abstract

Switching to alemtuzumab from fingolimod or other therapies: impact of wash-out period on disease activity

Abstract

T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment

Contributo in Atti di convegno

To switch therapies in RRMS: why and when? A real-life multicentre study

Contributo in Atti di convegno

Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP

Contributo in Atti di convegno

Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience

Articolo

Validation of the World Health Organization Disability Assessment Schedule II (WHODAS-II) in patients with multiple sclerosis

Articolo

e-Health and multiple sclerosis: An update

Articolo

eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54

Articolo

No Results Found

MULTIPLE SCLEROSIS

Dati Generali

Pubblicazioni (65)